Shiseido has announced its first six-month 2022 results, which showed net sales were 493,399 million yen, compared to 495,365 million yen in the previous year.
Core operating profit was 17,539 million yen, compared to 23,038 million yen in the previous year.
Gross profit was 363,054 million yen, compared to 146,558 million yen.
In the first six months of the fiscal year 2022, Shiseido achieved strong growth in net sales in travel retail business, the Americas, EMEA and Asia Pacific. Clé de Peau Beauté and Nars grew strongly and drove the growth.
Fiscal Year 2022 Forecast
Net sales are expected to be 1,070,000 million yen, a downward revision from the company's previous announcement in May 2022 anticipating net sales to be 1,075,00 million yen.
Core operating profit is expected to be 40,000 million yen, a revision from 60,000 million yen.
The Shiseido Beauty Innovations Fund has announced its first investment in collagen biomaterial expert Jiangsu Trautec Medical Technology Co., Ltd. (Trautec).
Shiseido will act as the lead investor with an investment of close to RMB 100 million. Furthermore, Shiseido will form a strategic partnership with Trautec to work together in areas such as product R＆D, raw material supply, and sales channels to accelerate the exploration of new areas in functional skin care.